How Do NSAIDs Prevent Colorectal Cancer
非甾体抗炎药如何预防结直肠癌
基本信息
- 批准号:8545125
- 负责人:
- 金额:$ 16.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-13 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:A MouseAdverse effectsAlgorithmsAspirinCell CountCellsChemopreventionChronicColorectal CancerDataDoseIndividualIntestinesLife StyleMalignant NeoplasmsMeasurementMeasuresMinorityMusMutationNon-Steroidal Anti-Inflammatory AgentsPharmaceutical PreparationsRiskScheduleSignal TransductionStem cellsTestingWorkcancer chemopreventioncancer riskcytotoxicimprovedintestinal cryptmouse modelmutantprevent
项目摘要
DESCRIPTION (provided by applicant): Chronic low dose aspirin use decreases colorectal cancer (CRC) risks. It is uncertain how chemoprevention by aspirin and other NSAIDs mechanistically reduce CRC risks. We propose that NSAIDs reduce CRC risks by augmenting natural "anticancer" crypt niche defenses. Crypt niches inherently reduce cancer risks with a stem cell hierarchy where stem cells are a minority of all cells. Random stem cell turnover (neutral drift) further reduces "average" numbers of stem cells per crypt and can also eliminate mutant stem cells via differentiation. Anything that increases neutral drift should decrease cancer risks by decreasing "average" stem cell numbers. We propose to test this hypothesis in a new mouse model that can measure stem cell neutral drift rates. Mutations (Apc) that predispose to cancer should slow neutral drift rates whereas NSAIDs, by modulating crypt niche signaling, should increase neutral drift rates, decreasing "average" stem cell numbers and cancer risks. Verifying that neutral drift rates correlate with cancer risks will identify the stemcell niche as a new specific chemoprevention target. A mouse model of neutral drift will facilitate the rapid testing of new drugs or dosing schedules that can effectively reduce "average" stem cell numbers with fewer side effects. Chemoprevention that augments natural crypt anticancer mechanisms is more likely to have fewer side effects than cytotoxic strategies.
描述(由申请人提供):慢性低剂量阿司匹林可降低结直肠癌(CRC)风险。阿司匹林和其他非甾体抗炎药的化学预防如何降低结直肠癌风险尚不确定。我们建议非甾体抗炎药通过增强天然的“抗癌”隐窝生态位防御来降低结直肠癌风险。隐窝小生境固有地降低癌症风险与干细胞层次,其中干细胞是所有细胞的少数。随机干细胞转换(中性漂移)进一步减少了每个隐窝干细胞的“平均”数量,也可以通过分化消除突变干细胞。任何增加中性漂移的物质都应该通过减少“平均”干细胞数量来降低癌症风险。我们建议在一种新的小鼠模型中测试这一假设,该模型可以测量干细胞中性漂移率。易患癌症的突变(Apc)应该减缓中性漂移率,而非甾体抗炎药通过调节隐窝生态位信号,应该增加中性漂移率,降低“平均”干细胞数量和癌症风险。验证中性漂移率与癌症风险相关将确定干细胞生态位作为新的特异性化学预防目标。中性漂移的小鼠模型将促进新药或剂量计划的快速测试,这些药物或计划可以有效地减少“平均”干细胞数量,同时减少副作用。增强天然隐窝抗癌机制的化学预防比细胞毒性策略更可能具有更少的副作用。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Darryl K Shibata其他文献
Darryl K Shibata的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Darryl K Shibata', 18)}}的其他基金
"Born to be Bad": Is Abnormal Cell Mobility Already Present At Initiation?
“生来就是坏的”:异常的细胞迁移性是否在开始时就已经存在?
- 批准号:
8686657 - 财政年份:2014
- 资助金额:
$ 16.18万 - 项目类别:
Tumor Diversity As A Biomarker For Colorectal Cancer
肿瘤多样性作为结直肠癌的生物标志物
- 批准号:
7874806 - 财政年份:2010
- 资助金额:
$ 16.18万 - 项目类别:
Tumor Diversity As A Biomarker For Colorectal Cancer
肿瘤多样性作为结直肠癌的生物标志物
- 批准号:
8050151 - 财政年份:2010
- 资助金额:
$ 16.18万 - 项目类别:
How Do Colorectal Cancers Arise Despite Surveillance?
尽管有监测,结直肠癌是如何发生的?
- 批准号:
7105101 - 财政年份:2005
- 资助金额:
$ 16.18万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 16.18万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 16.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 16.18万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 16.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 16.18万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 16.18万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 16.18万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 16.18万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 16.18万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 16.18万 - 项目类别:
Discovery Grants Program - Individual